Literature DB >> 16044982

Estimating medication persistency using administrative claims data.

Rishi Sikka1, Fang Xia, Ronald E Aubert.   

Abstract

OBJECTIVES: To review the definitions and methods for measuring medication persistency, and to propose a uniform definition of and calculation for persistency using pharmacy claims data. STUDY
DESIGN: Literature review.
METHODS: A MEDLINE search (1966 to present) was performed to identify articles detailing a definition or method of persistency measurement based on automated pharmacy data. Articles were screened for relevance by title and abstract. References from identified articles were used to expand the search results.
RESULTS: The concept behind medication persistency measurement is to capture the amount of time that an individual remains on chronic drug therapy. The methods to calculate medication persistency can be classified into 1 of 3 categories: (1) Persistency as a function of the medication possession ratio; (2) persistency as a function of medication availability at a fixed point in time; and (3) persistency as a function of the gaps between refills.
CONCLUSIONS: The common goal of all persistency measures should be to reflect the continuity of medication usage and to capture the timeliness and the frequency of refilling. The measurement of persistency as a function of the gaps between refills provides the best assessment of refill compliance across a variety of medication and disease states and lends itself to the well-established measurements of survival analysis.

Mesh:

Substances:

Year:  2005        PMID: 16044982

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  167 in total

1.  Race and medication adherence and glycemic control: findings from an operational health information exchange.

Authors:  Vivienne J Zhu; Wanzhu Tu; David G Marrero; Marc B Rosenman; J Marc Overhage
Journal:  AMIA Annu Symp Proc       Date:  2011-10-22

2.  How patient cost-sharing trends affect adherence and outcomes: a literature review.

Authors:  Michael T Eaddy; Christopher L Cook; Ken O'Day; Steven P Burch; C Ron Cantrell
Journal:  P T       Date:  2012-01

3.  Does medication adherence itself confer fracture protection? An investigation of the healthy adherer effect in observational data.

Authors:  Jeffrey R Curtis; Huifeng Yun; Jeff L Lange; Robert Matthews; Pradeep Sharma; Kenneth G Saag; Elizabeth Delzell
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-12       Impact factor: 4.794

4.  Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women.

Authors:  V Rabenda; R Mertens; V Fabri; J Vanoverloop; F Sumkay; C Vannecke; A Deswaef; G A Verpooten; J Y Reginster
Journal:  Osteoporos Int       Date:  2008-06       Impact factor: 4.507

5.  Resource Use Evaluation of Tobramycin Formulations in a State Medicaid Program.

Authors:  Shellie L Keast
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Mar-Apr

6.  Partners and Alerts in Medication Adherence: A Randomized Clinical Trial.

Authors:  Judd B Kessler; Andrea B Troxel; David A Asch; Shivan J Mehta; Noora Marcus; Raymond Lim; Jingsan Zhu; William Shrank; Troyen Brennan; Kevin G Volpp
Journal:  J Gen Intern Med       Date:  2018-03-15       Impact factor: 5.128

7.  Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia.

Authors:  Benjamin H Chi; Albert Mwango; Mark Giganti; Lloyd B Mulenga; Bushimbwa Tambatamba-Chapula; Stewart E Reid; Carolyn Bolton-Moore; Namwinga Chintu; Priscilla L Mulenga; Elizabeth M Stringer; Robert Sheneberger; Peter Mwaba; Jeffrey S A Stringer
Journal:  J Acquir Immune Defic Syndr       Date:  2010-05-01       Impact factor: 3.731

8.  New medication adherence scale versus pharmacy fill rates in seniors with hypertension.

Authors:  Marie Krousel-Wood; Tareq Islam; Larry S Webber; Richard N Re; Donald E Morisky; Paul Muntner
Journal:  Am J Manag Care       Date:  2009-01       Impact factor: 2.229

9.  Positive impact of compliance to strontium ranelate on the risk of nonvertebral osteoporotic fractures.

Authors:  V Rabenda; J-Y Reginster
Journal:  Osteoporos Int       Date:  2010-01-16       Impact factor: 4.507

10.  Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data.

Authors:  Simon Frey; Roland Linder; Georg Juckel; Tom Stargardt
Journal:  Eur J Health Econ       Date:  2013-02-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.